US equities
|
MU
$977.52
▲+5.25%
META
$617.78
▼-0.39%
SPCX
$143.13
▼-3.67%
TSLA
$399.38
▼-1.98%
SNDK
$1,370.01
▲+4.99%
NVDA
$218.06
▲+0.06%
SKHY
$162.05
▲+11.48%
GOOGL
$324.72
▲+1.29%
MU
$977.52
▲+5.25%
META
$617.78
▼-0.39%
SPCX
$143.13
▼-3.67%
TSLA
$399.38
▼-1.98%
SNDK
$1,370.01
▲+4.99%
NVDA
$218.06
▲+0.06%
SKHY
$162.05
▲+11.48%
GOOGL
$324.72
▲+1.29%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Amneal Pharmaceuticals, Inc. - Class A Common Stock
(NQ:
AMRX
)
21.59
+0.15 (+0.70%)
Delayed Quote
Updated: 10:06 AM EDT, Oct 28, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Amneal Pharmaceuticals, Inc. - Class A Common Stock
< Previous
1
2
3
4
5
Next >
1 Russell 2000 Stock with Competitive Advantages and 2 Facing Challenges
October 21, 2026
The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However,...
Via
StockStory
1 Profitable Stock for Long-Term Investors and 2 Facing Headwinds
October 13, 2026
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today does...
Via
StockStory
3 Overrated Stocks We Think Twice About
October 09, 2026
Great things are happening to the stocks in this article. They’re all outperforming the market over the last month because of positive catalysts such as a ne...
Via
StockStory
3 Low-Volatility Stocks with Open Questions
October 05, 2026
Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets. Lu...
Via
StockStory
Amneal Pharmaceuticals (NASDAQ:AMRX) Soars on Q2 Earnings Beat and Raised Guidance
↗
July 30, 2026
Via
Chartmill
Topics
Earnings
Why Is Amneal (AMRX) Stock Rocketing Higher Today
September 21, 2026
What Happened? Shares of pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) jumped 12.5% in the afternoon session after the company announced that t...
Via
StockStory
3 Reasons to Avoid AMRX and 1 Stock to Buy Instead
September 18, 2026
What a time it’s been for Amneal. In the past six months alone, the company’s stock price has increased by a massive 47.7%, reaching $18.31 per share. This w...
Via
StockStory
Generic Pharmaceuticals Stocks Q2 Results: Benchmarking Amneal (NASDAQ:AMRX)
August 30, 2026
Wrapping up Q2 earnings, we look at the numbers and key takeaways for the generic pharmaceuticals stocks, including Amneal (NASDAQ:AMRX) and its peers. The g...
Via
StockStory
Topics
Artificial Intelligence
Intellectual Property
1 Stock Under $50 with Solid Fundamentals and 2 Facing Challenges
August 26, 2026
Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However...
Via
StockStory
1 Russell 2000 Stock with Exciting Potential and 2 We Ignore
August 19, 2026
The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However,...
Via
StockStory
1 Healthcare Stock Worth Your Attention and 2 We Ignore
August 07, 2026
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Shareholders who bet on the industry...
Via
StockStory
5 Insightful Analyst Questions From Amneal’s Q2 Earnings Call
August 06, 2026
Amneal’s second quarter results reflected ongoing momentum driven by expanded product launches and strength across its core Affordable Medicines and Specialt...
Via
StockStory
Topics
Earnings
World Trade
AMRX Q2 Deep Dive: Diversified Product Mix and Biosimilars Strategy Shape Guidance
July 31, 2026
Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 9.9% year on ...
Via
StockStory
Amneal (AMRX) Q2 2026 Earnings Call Transcript
↗
July 30, 2026
Revenue hit $796 million as biosimilar strategy accelerates with Kashiv acquisition.
Via
The Motley Fool
Topics
Earnings
Amneal Pharmaceuticals Q2 Earnings Call Highlights
↗
July 30, 2026
Amneal Pharmaceuticals (NASDAQ:AMRX) reported second-quarter 2026 revenue of $796 million, up 10% from a year earlier, as growth in its affordable medicines and specialty businesses offset a decline at...
Via
MarketBeat
Topics
Earnings
Amneal (NASDAQ:AMRX) Beats Expectations in Strong Q2 CY2026, Stock Jumps 15.9%
July 30, 2026
Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 9.9% year on ...
Via
StockStory
Amneal (AMRX) Reports Q2: Everything You Need To Know Ahead Of Earnings
July 28, 2026
Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) will be announcing earnings results this Thursday before market hours. Here’s what to expect. Amn...
Via
StockStory
Spotting Winners: Amneal (NASDAQ:AMRX) And Generic Pharmaceuticals Stocks In Q1
July 27, 2026
Wrapping up Q1 earnings, we look at the numbers and key takeaways for the generic pharmaceuticals stocks, including Amneal (NASDAQ:AMRX) and its peers. The g...
Via
StockStory
Topics
Artificial Intelligence
Intellectual Property
3 Reasons AMRX is Risky and 1 Stock to Buy Instead
July 15, 2026
Amneal currently trades at $16.70 and has been a dream stock for shareholders. It’s returned 283% since July 2021, blowing past the S&P 500’s 72.3% gain. The...
Via
StockStory
Topics
Stocks
Generic Pharmaceuticals Stocks Q4 In Review: Amneal (NASDAQ:AMRX) Vs Peers
July 06, 2026
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the generic pharmaceuticals industry, including Amneal (NASDAQ:AM...
Via
StockStory
Topics
Artificial Intelligence
Intellectual Property
1 Mooning Stock Worth Your Attention and 2 We Question
June 29, 2026
Exciting developments are taking place for the stocks in this article. They’ve all surged ahead of the broader market over the last month as catalysts such a...
Via
StockStory
1 Small-Cap Stock for Long-Term Investors and 2 We Find Risky
June 17, 2026
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that ...
Via
StockStory
3 Russell 2000 Stocks with Open Questions
June 10, 2026
The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size ...
Via
StockStory
Amneal Pharmaceuticals Bets on Biosimilars, Patches to Power Next Growth Phase
↗
June 09, 2026
Amneal Pharmaceuticals (NASDAQ:AMRX) Co-Founder, President and Co-Chief Executive Officer Chirag Patel said the company is entering a stronger growth phase, driven by momentum in its existing generics...
Via
MarketBeat
Why Amneal (AMRX) Stock Is Trading Up Today
June 04, 2026
What Happened? Shares of pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) jumped 5.7% in the afternoon session after the U.S. Food and Drug Admini...
Via
StockStory
3 Profitable Stocks with Open Questions
June 04, 2026
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today does...
Via
StockStory
Topics
Economy
Q4 Earnings Highlights: Amneal (NASDAQ:AMRX) Vs The Rest Of The Generic Pharmaceuticals Stocks
May 26, 2026
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ...
Via
StockStory
Topics
Artificial Intelligence
Intellectual Property
2 Reasons AMRX is Risky and 1 Stock to Buy Instead
May 12, 2026
Amneal trades at $12.64 and has moved in lockstep with the market. Its shares have returned 6.2% over the last six months while the S&P 500 has gained 7.9%. ...
Via
StockStory
Topics
Artificial Intelligence
Stocks
Amneal (AMRX) Q3 2025 Earnings Call Transcript
↗
May 04, 2026
Amneal (AMRX) Q3 2025 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
Amneal (AMRX) Q2 2025 Earnings Transcript
↗
May 04, 2026
Amneal (AMRX) Q2 2025 Earnings Transcript
Via
The Motley Fool
Topics
Supply Chain
< Previous
1
2
3
4
5
Next >
